Q4 2020 Photocure ASA Earnings Call Transcript
All right. Well, good afternoon and good morning, depending on where you're calling in from around the world. This is Photocure's results for year-end and fourth quarter 2020. I'm Dan Schneider, President and CEO. And with me today is Erik Dahl, CFO.
Usual disclaimers are in place for today's presentation. So let's go with a little bit of the background on Photocure and the product Hexvix/Cysview. We treated over 0.5 million bladder cancer patients worldwide. In fact, I think the number has reached 637,000 and growing rapidly. We have direct sales in both the U.S. and Europe. And otherwise, worldwide partnerships around the globe, recently announcing our China partnership with Asieris.
We do about NOK 256.5 million in 2020. We're approved for use in over 30 countries. We currently have 90 employees, as we've recently built our European operations up. And as I said, we treated well over 0.5 million patients.
Our strategy is pretty straightforward. Strategy steps 1 and 2 are focused on Hexvix/Cysview, ways to accelerate the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
